gilead.com

Website beoordeling gilead.com

 Gegenereerd op December 14 2022 00:39 AM

Oude statistieken? UPDATE !

De score is 56/100





SEO Content

Title

Gilead Sciences, Inc.

Lengte : 21

Let op, uw title tag zou tussen de 40 en 70 karakters (spaties inbegrepen) moeten bevatten. Gebruik deze gratis tool om tekst lengte te berekenen.

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Lengte : 153

Perfect, uw meta description bevat tussen de 90 en 160 karakters.

Keywords

Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.

Og Meta Properties

Goed, uw page maakt gebruik van Og Properties.

Property Content
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Headings

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Afbeeldingen

We vonden 16 afbeeldingen in de pagina.

Goed, de meeste of alle afbeeldingen hebben een alt tekst

Text/HTML Ratio

Ratio : 40%

Ideaal! De ratio van text tot HTML code is tussen de 25 en 70 procent.

Flash

Perfect, geen Flash content gevonden in uw website.

Iframe

Jammer, u heeft Iframes in uw website, dit betekent dat deze content niet kan worden geïndexeerd.

Herschreven URL

Perfect. Uw links zien er vriendelijk uit!

Underscores in de URLs

Perfect! Geen underscores gevonden in uw URLs.

In-page links

We vonden een totaal van 161 links inclusie 1 link(s) naar bestanden

Ankertekst Type samenstelling
Medicine Questions Extern doFollow
Report an Adverse Event Intern doFollow
Investors Intern doFollow
Contact Intern doFollow
Canada Extern doFollow
Mexico Intern doFollow
USA Intern doFollow
Argentina Intern doFollow
Brazil Intern doFollow
China Mainland Extern doFollow
Hong Kong Intern doFollow
India Intern doFollow
Japan Extern doFollow
Korea Extern doFollow
Singapore Intern doFollow
Taiwan Intern doFollow
Israel Extern doFollow
Saudi Arabia Intern doFollow
Türkiye Intern doFollow
United Arab Emirates Intern doFollow
South Africa Intern doFollow
Australia and New Zealand Intern doFollow
Austria Intern doFollow
Belgium and Luxembourg Extern doFollow
Czech Republic & Slovakia Intern doFollow
Denmark Intern doFollow
Finland Intern doFollow
France Extern doFollow
Germany Extern doFollow
Greece Intern doFollow
Iceland Intern doFollow
Ireland Intern doFollow
Italy Extern doFollow
Netherlands Intern doFollow
Norway Intern doFollow
Poland & The Baltics Intern doFollow
Portugal Intern doFollow
Romania Intern doFollow
Russia Intern doFollow
Spain Extern doFollow
Sweden Intern doFollow
Switzerland Intern doFollow
United Kingdom Extern doFollow
Mission and Core Values Intern doFollow
Partnerships and Community Intern doFollow
Inclusion and Diversity Intern doFollow
Corporate Giving Intern doFollow
Gilead Foundation Intern doFollow
Sustainability Intern doFollow
Advancing Global Health Intern doFollow
Medication Access Intern doFollow
Leadership Intern doFollow
How We Operate Intern doFollow
Ethics and Code of Conduct Intern doFollow
Therapeutic Areas Intern doFollow
Medicines Intern doFollow
Pipeline Intern doFollow
Research Intern doFollow
Clinical Trials Extern doFollow
Events Intern doFollow
Stories Intern doFollow
Newsroom Intern doFollow
Company Statements Intern doFollow
Annual Reports Intern doFollow
Careers at Gilead Intern doFollow
Our Culture Intern doFollow
Meet Our Employees Intern doFollow
Inclusion and Diversity in Hiring Intern doFollow
Compensation, Benefits and Wellbeing Intern doFollow
Our Global Footprint Intern doFollow
Early Career Opportunities Intern doFollow
Postdoctoral Fellowships Intern doFollow
Hiring Events Extern doFollow
Talent Community Sign-up Extern doFollow
Privacy Statements Intern doFollow
Terms Of Use Intern doFollow
Social Media Guidelines Intern doFollow
EU Data Disclosure Intern doFollow
Sitemap Intern doFollow
BACK TO MAIN MENU Intern doFollow
COMPASS Initiative Intern doFollow
HepConnect Intern doFollow
HIV Age Positively Intern doFollow
Lift Intern doFollow
RADIAN Intern doFollow
TRANScend Intern doFollow
What We Fund Intern doFollow
Funding Requests Intern doFollow
Zeroing In: Ending the HIV Epidemic Intern doFollow
Creating Possible Fund Intern doFollow
Our Business Is Sustainable Intern doFollow
Performance Intern doFollow
Reporting Intern doFollow
U.N. Global Compact Intern doFollow
U.N. Sustainable Development Goals Intern doFollow
COVID-19 Intern doFollow
HCV Elimination Intern doFollow
U.S. Patient Access Intern doFollow
Disaster Product Replacement Intern doFollow
Global Access Intern doFollow
Authorized Distributors Intern doFollow
ESG Goals Intern doFollow
Governance Intern doFollow
Transparency Intern doFollow
Policies Intern doFollow
Anti-Bribery and Anti-Corruption Policy Intern doFollow
Animal Use and Welfare Policy Intern doFollow
Disclosures Intern doFollow
Anti-Counterfeiting Intern doFollow
Consumer Product Safety Intern doFollow
Supplier Information Intern doFollow
Political Engagement Intern doFollow
Research Scholars Program Intern doFollow
Compassionate Use Intern doFollow
Investigator-Sponsored Research Intern doFollow
Press Releases Intern doFollow
Media Inquiries Intern doFollow
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Intern doFollow
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Intern doFollow
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Intern doFollow
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Intern doFollow
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Intern doFollow
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Intern doFollow
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Intern doFollow
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Intern doFollow
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Intern doFollow
Gilead to Expand Footprint in Oceanside Intern doFollow
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Intern doFollow
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Intern doFollow
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Intern doFollow
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Intern doFollow
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Intern doFollow
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Intern doFollow
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Intern doFollow
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Intern doFollow
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Intern doFollow
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Intern doFollow
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Intern doFollow
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Intern doFollow
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Intern doFollow
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Intern doFollow
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Intern doFollow
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Intern doFollow
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Intern doFollow
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Intern doFollow
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Intern doFollow
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Intern doFollow
Gilead Sciences Statement on Recent Events in Washington, D.C. Intern doFollow
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Intern doFollow
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Intern doFollow
- Intern doFollow
- Intern doFollow
Year in Review 2021 Intern doFollow
Cookie Statement Intern doFollow
Partnership Request Intern doFollow
Gilead Sciences Again Named to Dow Jones Sustainability World Index Intern doFollow
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Intern doFollow
- Extern doFollow
Stories@Gilead Intern doFollow
Investor Calls Intern doFollow
Modern Slavery Act Statement Intern doFollow

SEO Keywords

Keywords Cloud

community      menu      statement      gilead      main      remdesivir      back      together      sciences      hiv     

Keywords Consistentie

Keyword Content Title Keywords Description Headings
gilead 37
back 16
main 16
menu 16
statement 16

Bruikbaarheid

Url

Domein : gilead.com

Lengte : 10

Favicon

Goed, uw website heeft een favicon.

Printbaarheid

Jammer. We vonden geen Print-Vriendelijke CSS.

Taal

Goed. Uw ingestelde taal is en.

Dublin Core

Deze pagina maakt geen gebruik van Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Uw ingestelde Charset is UTF-8.

W3C Validiteit

Fouten : 12

Waarschuwingen : 15

E-mail Privacy

Waarschuwing! Er is op zijn minst 1 e-mailadres gevonden als platte tekst. (voorkom spam!). Gebruik deze gratis antispam protector om e-mailadressen te verbergen voor spammers.

Niet ondersteunde HTML

Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.

Speed Tips

Geweldig, uw website heeft geen tabellen in een tabel.
Jammer, uw website maakt gebruik van inline styles.
Geweldig, uw website heeft een correct aantal CSS bestanden.
Jammer, uw website heeft teveel JS bestanden (meer dan 6).
Perfect, uw website haalt voordeel uit gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimalisatie

XML Sitemap

Ontbrekend

Uw website heeft geen XML sitemap- dit kan problematisch zijn.

Een sitemap vermeld url's die beschikbaar zijn voor crawlen en kan extra informatie bevatten zoals uw laatste site-updates, frequentie van wijzigingen en het belang van de url's. Dit laat zoekmachines toe om de site intelligenter te doorzoeken.

Robots.txt

http://gilead.com/robots.txt

Geweldig uw website heeft een robots.txt bestand.

Analytics

Ontbrekend

We hadden niet op te sporen van een analytics tool op deze website geplaatst.

Web Analytics laat u toe de bezoekersactiviteit op uw website te meten. U zou minstens 1 Analytics tool geïnstalleerd moeten hebben en een extra tool voor de bevestiging van de resultaten.

PageSpeed Insights

Device
Categorieën

Website Review

Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren